Xlife Sciences Action: Kleiner Gewinn im Halbjahr | 19.09.24

Das Unternehmen has connected the Fortschritte in the seiner Geschäftsentwicklung.

The Unternehmen are in the first period of a year one of the 0.5 Prozent higher Umsatzerlös von 349’818 Franken, with Xlife Sciences in the Donnerstag miteilte. Under the law, the result is a gain for an action of 0.08 francs, during the previous period nor a gain in action of 1.10 francs. a fallen war.

We are proud to say that we have developed new partnerships and development in the new market and our portfolio can be diversified and expanded further. The Bilanzsumme des Unternehmens remains at 509.9 Mio Francs after 477.9 Millions in the Vorjahre period.

A crossroads in the first half of 2024 has been one of the company’s international operations, uninterrupted by its existing collaboration in Abu Dhabi with partners including Thermo Fisher Scientific and Masdar City. These partnerships position Xlife Sciences to excel.

Xlife Sciences sees itself as an incubator and accelerator for Life Sciences entrepreneurs, who develop in the environment of the University and Research Institutes and will help, their search for commercialization. These can be used via Lizenzvergaben, Partnerships or Börsengänge geschehen.

Since most of the years consist of the Gesellschaft, further strategic milestones were planted. Two portfolios with the “Proof of Concept” status were a solid basis for the future portfolio he had.

Zurich (awp)